Lisata Therapeutics Q2 2025 Earnings Report

Lisata Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.64
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lisata Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lisata Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/11/2025
• Time: After Market Closes
• Conference Call Date: Monday, August 11, 2025
• Conference Call Time: 4:30PM ET

Lisata Therapeutics (NASDAQ:LSTA) (NASDAQ: LSTA) is a Seattle-based clinical-stage biopharmaceutical company dedicated to the discovery and development of novel protein therapeutics for oncology. The company harnesses a proprietary protein engineering platform to optimize the immune response against solid tumors while minimizing systemic toxicity. Lisata’s research is centered on delivering next-generation cytokine-based therapies that aim to reshape the tumor microenvironment and enhance anti-tumor immunity.

The company’s lead program, LSTA1, is a next-generation interleukin-2 (IL-2) variant engineered to preferentially activate effector T cells and natural killer (NK) cells within the tumor milieu, while reducing engagement with cell populations associated with adverse effects. LSTA1 is currently being evaluated in early-phase clinical trials in patients with advanced solid tumors, either as a monotherapy or in combination with established checkpoint inhibitors. In addition to LSTA1, Lisata’s pipeline includes albumin-fused IL-2 variants and antibody–cytokine fusion proteins designed to extend half-life and improve targeting to tumor tissues.

Lisata was established in 2019 as a spin-out from CTI BioPharma’s protein therapeutic division, with the intent to singularly focus on next-generation immuno-oncology approaches. Since its inception, the company has expanded its presence beyond North America, forging collaborations with academic research centers in Europe and Asia to enable global clinical development. Strategic partnerships with contract manufacturing organizations facilitate scalable production of Lisata’s proprietary protein constructs under current Good Manufacturing Practice (cGMP) standards.

The executive team is composed of seasoned industry professionals drawn from leading biotechnology and pharmaceutical companies. The leadership team’s collective experience spans drug discovery, translational development, and commercial strategy, providing a solid foundation for advancing Lisata’s pipeline through clinical milestones. Under the guidance of the board of directors, Lisata Therapeutics remains committed to pioneering safe and effective protein-based immunotherapies with the potential to transform cancer care worldwide.